Israel’s CytoReason Launches AI Drug Discovery Platform In Japanese Market
Israeli AI company Cytoreason develops computational disease models of the human immune system for discovery and clinical drug development.
September 30, 2021
Sponsored by the Asper Foundation and Reichman University
